BR112022013544A2 - Anticorpo monoclonal anti-lag3 e método de preparação do mesmo e uso do mesmo - Google Patents
Anticorpo monoclonal anti-lag3 e método de preparação do mesmo e uso do mesmoInfo
- Publication number
- BR112022013544A2 BR112022013544A2 BR112022013544A BR112022013544A BR112022013544A2 BR 112022013544 A2 BR112022013544 A2 BR 112022013544A2 BR 112022013544 A BR112022013544 A BR 112022013544A BR 112022013544 A BR112022013544 A BR 112022013544A BR 112022013544 A2 BR112022013544 A2 BR 112022013544A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- preparing
- monoclonal anti
- lag3
- lag3 antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010069008 | 2020-01-21 | ||
| PCT/CN2021/072610 WO2021147837A1 (zh) | 2020-01-21 | 2021-01-19 | 抗lag3单克隆抗体及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013544A2 true BR112022013544A2 (pt) | 2022-09-06 |
Family
ID=76993109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013544A BR112022013544A2 (pt) | 2020-01-21 | 2021-01-19 | Anticorpo monoclonal anti-lag3 e método de preparação do mesmo e uso do mesmo |
Country Status (10)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| EP4410835A4 (en) * | 2021-09-29 | 2025-09-24 | Akeso Biopharma Inc | ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE |
| WO2023138677A1 (en) * | 2022-01-24 | 2023-07-27 | Crown Bioscience Inc. (Taicang) | Novel anti-lag3 antibodies and derivative products |
| CN119950708B (zh) * | 2023-06-05 | 2025-12-26 | 北京东方百泰生物科技股份有限公司 | 一种抗il-11单克隆抗体的药物制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN114853891A (zh) * | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| US20190330336A1 (en) * | 2015-11-19 | 2019-10-31 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| SI4339615T1 (sl) | 2016-09-16 | 2026-01-30 | Shanghai Henlius Biotech, Inc. | Protitelesa anti-pd-1 za uporabo pri zdravljenju raka |
| UA128387C2 (uk) * | 2017-04-05 | 2024-07-03 | Ф. Хоффманн-Ля Рош Аг | Антитіло до lag3 |
| US11339218B2 (en) * | 2017-05-10 | 2022-05-24 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Human monoclonal antibodies against LAG3 and uses thereof |
| WO2019164219A1 (en) * | 2018-02-20 | 2019-08-29 | Institute For Basic Science | Anti-angiopoietin-2 antibodies and uses thereof |
| CN110204614B (zh) | 2018-02-28 | 2022-07-12 | 广州誉衡生物科技有限公司 | 抗人lag-3单克隆抗体及其制备方法和用途 |
| CN110305215B (zh) | 2018-03-20 | 2023-11-03 | 基石药业 | 新型抗lag-3抗体多肽 |
| CN110343179B (zh) | 2018-04-02 | 2024-03-08 | 上海博威生物医药有限公司 | 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途 |
| CN110172099B (zh) | 2018-08-16 | 2020-03-03 | 上海健信生物医药科技有限公司 | 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途 |
-
2021
- 2021-01-19 JP JP2022544146A patent/JP7692918B6/ja active Active
- 2021-01-19 US US17/759,180 patent/US20230074657A1/en active Pending
- 2021-01-19 CN CN202180008891.3A patent/CN114945595A/zh active Pending
- 2021-01-19 CA CA3165211A patent/CA3165211A1/en active Pending
- 2021-01-19 KR KR1020227028342A patent/KR20220131279A/ko active Pending
- 2021-01-19 BR BR112022013544A patent/BR112022013544A2/pt unknown
- 2021-01-19 AU AU2021210029A patent/AU2021210029A1/en active Pending
- 2021-01-19 EP EP21744582.4A patent/EP4095159A4/en active Pending
- 2021-01-19 WO PCT/CN2021/072610 patent/WO2021147837A1/zh not_active Ceased
-
2022
- 2022-07-26 ZA ZA2022/08339A patent/ZA202208339B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4095159A1 (en) | 2022-11-30 |
| EP4095159A4 (en) | 2024-03-20 |
| CA3165211A1 (en) | 2021-07-29 |
| US20230074657A1 (en) | 2023-03-09 |
| AU2021210029A1 (en) | 2022-09-01 |
| JP7692918B2 (ja) | 2025-06-16 |
| ZA202208339B (en) | 2023-11-29 |
| JP7692918B6 (ja) | 2025-07-17 |
| KR20220131279A (ko) | 2022-09-27 |
| JP2023510982A (ja) | 2023-03-15 |
| WO2021147837A1 (zh) | 2021-07-29 |
| CN114945595A (zh) | 2022-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| BR112021024553A2 (pt) | Molécula de ligação específica para cd73 e uso de molécula de ligação | |
| BR112022001460A2 (pt) | Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção | |
| BRPI0607757A2 (pt) | anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo | |
| BR112018077375A2 (pt) | kits, moléculas de anticorpo biespecífico trivalente, composição farmacêutica, vetor de expressão, célula hospedeira e método para a produção de uma molécula de anticorpo biespecífico trivalente | |
| BRPI0507489A (pt) | anticorpos humanos de anti-cd38 e para os seus usos | |
| ZA202208339B (en) | Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof | |
| MX2024009690A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| BR112018074325A2 (pt) | anticorpo para ligação a receptor de interleucina 4 | |
| BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
| BR112015017548A8 (pt) | construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| BR112012009289A8 (pt) | Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp) | |
| BR112023005674A2 (pt) | Construtos anti-cd93 e usos dos mesmos | |
| CL2016001134A1 (es) | Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento. | |
| BR112019005129A2 (pt) | anticorpos anti-pd-1 | |
| BR112021018608A2 (pt) | Anticorpos para claudina-6 e conjugados de fármaco | |
| BR112021022171A2 (pt) | Anticorpo para tigit, seu uso e método para produzir o mesmo | |
| BR112023000826A2 (pt) | Anticorpo anti-ctla-4 e uso do mesmo | |
| BR112023017887A2 (pt) | Proteína compreendendo um primeiro polipeptídeo e um segundo polipeptídeo, anticorpo biespecífico, ácido nucleico de codificação do dito primeiro ou segundo polipeptídeo, célula hospedeira, composição farmacêutica, proteína, anticorpo biespecífico ou composição farmacêutica para uso, e, métodos de tratamento e de preparo de um anticorpo biespecífico | |
| BR112022019129A2 (pt) | Anticorpos de ligação a siglec15 e usos dos mesmos | |
| CO2025017440A2 (es) | Anticuerpos de dominio único modificados | |
| MX2024014591A (es) | Anticuerpo anti-bdca2 y uso del mismo | |
| BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer |